Skip to content

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

The Effect of Aminophylline on Preventing Acute Kidney Injury in Pediatric Patients Undergoing Open Heart Surgery

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03897335
Acronym
AKI
Enrollment
80
Registered
2019-04-01
Start date
2019-02-07
Completion date
2024-02-01
Last updated
2022-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Aminophylline

Brief summary

The purpose of this study is to compare the effects of peri-operative administration of Aminophylline versus Saline placebo in the preservation of renal function and the attenuation of renal injury in pediatric patients undergoing open heart surgery.

Detailed description

Cardiac palliative/ correction surgeries in pediatric patients involve significant morbidity and mortality risks. Kidney function is frequently affected from cardiac surgery in these children. Studies identify the incidence of acute kidney injury (AKI) to be approximately 54% when defined by serum biomarkers (e.g. serum creatinine) and urine output criteria. The need for renal replacement therapy (RRT) for newborns and infants after cardiac surgery is reported as 2% to 17% in the literature. There are several reported risk factors for the development of AKI in this population. These are the complexities of the underlying heart disease and the surgical procedure, duration of cardiopulmonary bypass, functional single ventricle heart disease, circulatory arrest and low cardiac output syndrome in the post-operative period. AKI can cause worsening fluid overload compromising ventilation and lung function, predisposition to overwhelming infections and cytokine-mediated inflammatory state. The presence of AKI significantly increases the mortality that is associated with cardiac surgery in these very young patients, reported as high as 79% in the literature. There have been several reports suggesting that early intervention with AKI using renal replacement therapy (RRT) may improve patient mortality. Successful prevention strategies for AKI have not been reported for this high-risk population. Adenosine has been demonstrated to regulate renal circulation and metabolism. It is a breakdown product of adenosine triphosphate/adenosine diphosphate (ATP/ADP) metabolism and accumulates in AKI. At baseline, the barely detectable renal parenchymal adenosine levels can increase to 10-100 times following an ischemic insult. These are typical seven trans-membrane spanning domains with a coupled G-protein at the intracellular end. Adenosine receptors are located ubiquitously in many tissues. Adenosine acts as a vasodilator in all other tissues but the renal parenchyma. The interaction of AT-II with adenosine converts adenosine to a vasoconstrictor in renal microvasculature. Adenosine acts on the A1 receptors (A1 R) in the afferent arterioles, causing reduced glomerular blood flow and glomerular filtration rate (GFR), as well as stimulating renin release from the kidney parenchyma. Adenosine plays an important role in generating the vasoconstrictive response in the renal vasculature to hypoxia and ischemia. Early interventions by blocking the actions of adenosine on A1 R may restore glomerular blood flow and recover GFR. The study rationale is that Aminophylline and Theophylline are competitive non-selective inhibitors of adenosine. Therefore, even though aminophylline infusion (iv) has no effect on renal blood flow rate at baseline, it can ameliorate the decrease in renal blood flow rate following adenosine infusion. This property can improve renal function when the main mechanism of insult induces vasoconstriction. Both early and late administration of aminophylline protects renal function after ischemia-reperfusion injury in rats. Aminophylline has also been reported to successfully reverse newborn renal failure, prevent renal failure in perinatal asphyxia, and reverse acute kidney injury secondary to calcineurin induced nephropathy. Both theophylline and aminophylline have been used for prophylaxis of renal impairment during aorto-coronary bypass surgery in adults and the results have not been consistent for either a positive or negative effect. There have been no trials reported on the effect of aminophylline or theophylline to prevent or ameliorate acute kidney injury in children with congenital heart defects going through cardiac surgery. Additionally, we are examining the components of serotonin biosynthesis to determine if these levels can act as markers of acute kidney injury in pediatric patients undergoing open heart surgery.

Interventions

DRUGAminophylline

Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.

DRUGPlacebo

The placebo group will not receive any aminophylline treatments for the first post-op five days

Sponsors

Le Bonheur Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

Cohort 1 will consist of all children undergoing open heart surgery for congenital heart defects with or without circulatory arrest, and Cohort 2 will consist of Orthotopic heart transplantation patients. All subjects will be randomized 1:1 to aminophylline or saline placebo. Cohort 1 will be randomized using block-stratification with stratification factors age (neonate vs infant) and circulatory arrest (yes vs no). Age will be categorized as neonates (0 to \<28 days) and infants (28 days to \<1 year). A total of 80 (60 in Cohort 1 and 20 in Cohort 2) participants are expected to be enrolled on this study.

Intervention model description

1 Patient randomization groups A) Group 1: Aminophylline pre CPB & immediately post cardiopulmonary bypass (CPB) B) Group 2: No aminophylline prophylaxis

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

Cohort 1 * All children undergoing open heart surgery for congenital heart defects with or without circulatory arrest * Neonates (\<28 days old) and infants (\<1 years of age) * Hypoplastic L heart syndrome or its variants. * Coarctation with aortic arch hypoplasia. * Interrupted aortic arch. * TAPVR (Total anomalous pulmonary venous return) * Patients with complex congenital heart defects Cohort 2: * Orthotopic heart transplantation patients. * Patients ≤ 18 years of age * Congenital heart defects * Cardiomyopathy (Dilated/Hypertrophic/Restrictive/Left Ventricular Non-compaction)

Exclusion criteria

* Children under the age of 12 months undergoing bypass for any condition that is not categorized as congenital heart defect * History of seizures * History of significant tachyarrhythmia.

Design outcomes

Primary

MeasureTime frameDescription
Acute kidney injury state II/III by AKIN criteriaAt 48 hours post-operativeAcute kidney injury state II/III by AKIN criteria

Secondary

MeasureTime frameDescription
Urine output during post opfirst 12 hours post opUrine output during post op
Concentration of Delta serum cystatin C24 hours post CPBDelta serum cystatin C
Acute kidney injury stagemax point within post CPB 72 hoursAcute kidney injury stage Pediatric modified Acute Kidney Injury Network criteria (pAKIN) AKI Stage I-\<0.5mL (milliliter)/kg/hour for 8 hours AKI Stage II-\<0.5mL/kg/hour for 16 hours AKI Stage III-\<0.3mL/kg/hour for 24 hours OR Anuria for 16 hours Using serum creatinine and AKIN criteria

Other

MeasureTime frameDescription
Time to discharge from cardiovascular intensive care unit (CVICU) (days)during hospitalization, approximate 5 daysTime to discharge from CVICU (days)
Duration of hospital stay (Days).during hospitalization, approximate 8 daysDuration of hospital stay (Days).
Time to return to preoperative weight.during hospitalization, approximate 8 daysTime to return to preoperative weight.
Dialysis requirement (yes/no)during hospitalization, approximate 5 daysDialysis requirement (yes/no)
Peritoneal dialysis catheter output.during hospitalization, up to 8 daysPeritoneal dialysis catheter output through study completion
Transfusion requirements intraoperatively and postoperativelyduring hospitalization, up to 8 daysTransfusion requirements intraoperatively and postoperatively through study completion
Inotropic scoreat 7 days post operativeInotropic score Calculation of Inotropic score (IS) and Vasoactive inotropic score (VIS). IS(a) = dopamine dose (lg/kg/min) ? dobutamine dose (lg/kg/min) ? 100 9 epinephrine dose (lg/kg/min) VIS(b) = IS ? 10 9 milrinone dose (lg/kg/ min) ? 10,000 9 vasopressin dose (U/kg/ min) ? 100 9 norepinephrine dose (lg/kg/min) IS inotrope score, VIS vasoactive-inotropic score
Concentration of Delta urinary neutrophil gelatinase-associated lipocalin (NGAL)at 2 hours post CPB.1 Delta urinary NGAL at 6 hours post cardiopulmonary (CPB) and Delta plasma NGAL at 2 hours post CPB.
Time to extubation (hours)during hospitalization, up to 8 daysTime to extubation (hours) number of hours post surgery
Time to chest closure (hours)during hospitalization, up to 3 daysTime to chest closure (hours) from start time of incision to chest closure during procedure

Countries

United States

Contacts

Primary ContactLauren Davis
lauren.davis2@lebonheur.org901-287-4594
Backup ContactKerry Moore, RN
kerry.moore@lebonheur.org901-287-6871

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026